Related Experiment Video
Updated: May 12, 2026
11:53
Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome
Published on: May 10, 2022
Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report.
Christie Walker1, Shawky Z A Badawy
1Department of Obstetrics and Gynecology, Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA.
Case Reports in Obstetrics and Gynecology
|March 28, 2013
Summary
Depot medroxyprogesterone acetate (DMPA), a popular contraceptive, can cause vaginal dryness and painful intercourse due to hypoestrogenism. This case highlights vaginal atrophy as a potential side effect of long-term DMPA use.
Area of Science:
- Reproductive Endocrinology
- Gynecology
- Pharmacology
Background:
- Depot medroxyprogesterone acetate (DMPA) is a widely utilized injectable contraceptive known for its efficacy.
- DMPA functions by suppressing ovulation, which can lead to hypoestrogenic effects.
- Hypoestrogenism is associated with genitourinary symptoms such as vaginal dryness and dyspareunia.
Purpose of the Study:
- To report a case of significant vaginal atrophic changes in a patient using DMPA.
- To highlight the potential for DMPA-induced hypoestrogenism to manifest as symptomatic vaginal atrophy.
- To underscore the importance of recognizing this side effect, especially with increasing long-term DMPA use.
Main Methods:
- Clinical case presentation.
- Assessment of vaginal atrophy using vaginal cytology.
- Review of patient's medical history and contraceptive use.
Main Results:
- The patient presented with pronounced symptoms of vaginal atrophy.
- Vaginal cytology confirmed atrophic changes consistent with hypoestrogenism.
- These changes were attributed to the long-term use of DMPA.
Conclusions:
- Long-term use of depot medroxyprogesterone acetate (DMPA) may lead to symptomatic vaginal atrophy.
- Vaginal cytology is a useful diagnostic tool for identifying DMPA-induced hypoestrogenic effects.
- Clinicians should consider vaginal atrophy as a potential side effect in patients on long-term DMPA therapy.
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:05Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
01:28Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...